Results 281 to 290 of about 182,387 (331)
Some of the next articles are maybe not open access.
Current Oncology Reports, 2000
Angiogenesis inhibitors target the neovascular development that is hypothesized to underlie tumor growth. The inhibitors that are undergoing the clinical testing phase can be divided into five categories based on their target activity: 1) drugs that block matrix breakdown; 2) drugs that inhibit endothelial cells directly; 3) drugs that block ...
Walter M. Stadler +2 more
openaire +3 more sources
Angiogenesis inhibitors target the neovascular development that is hypothesized to underlie tumor growth. The inhibitors that are undergoing the clinical testing phase can be divided into five categories based on their target activity: 1) drugs that block matrix breakdown; 2) drugs that inhibit endothelial cells directly; 3) drugs that block ...
Walter M. Stadler +2 more
openaire +3 more sources
Src Inhibitors and Angiogenesis
Current Pharmaceutical Design, 2007Angiogenesis is a tightly regulated process that leads to the formation of new blood vessels in limited physiological conditions, and can also occur under pathological situations as retinopathies, arthritis, endometriosis and cancer. Enhanced angiogenesis is present in tumors that need new blood capillaries to grow, remove metabolic waste and transport
SCHENONE S +2 more
openaire +6 more sources
Endogenous Inhibitors of Angiogenesis [PDF]
Cancer Research, 2005 Abstract Angiogenesis, the formation of new blood vessels, is required for many pathologic processes, including invasive tumor growth as well as physiologic organ/tissue maintenance. Angiogenesis during development and adulthood is likely regulated by a balance between endogenous proangiogenic and antiangiogenic factors. It is speculated
Pia Nyberg, Raghu Kalluri, Liang Xie
openaire +2 more sources
2015
Angiogenesis plays a pivotal role in malignant, ischemic, inflammatory, infectious and immune disorders. The increasing molecular understanding of angiogenic processes fostered the development of strategies to induce or inhibit angiogenesis for therapeutic purposes.
H. Büning, U. T. Hacker
openaire +3 more sources
Angiogenesis plays a pivotal role in malignant, ischemic, inflammatory, infectious and immune disorders. The increasing molecular understanding of angiogenic processes fostered the development of strategies to induce or inhibit angiogenesis for therapeutic purposes.
H. Büning, U. T. Hacker
openaire +3 more sources
Endogenous angiogenesis inhibitors [PDF]
APMIS, 2004 When the FDA commissioner announced in February 2004 the approval of Avastin for the treatment of patients with colon cancer, he called angiogenesis inhibitors a fourth modality of anti‐cancer therapy. Because angiogenesis inhibitors are relatively less toxic than conventional chemotherapy and have a lower risk of drug resistance, they may also ...
openaire +2 more sources
Protamine is an inhibitor of angiogenesis
Nature, 1982Protamine is shown to be a specific inhibitor of angiogenesis. The compound inhibits the capillary proliferation observed in embryogenesis, inflammation, certain immune reactions and the growth of solid tumours.
Judah Folkman, Stephanie Taylor
openaire +2 more sources
Update on angiogenesis inhibitors
Current Opinion in Oncology, 2005A number of therapeutic agents have been developed which have anti-angiogenic potential. Here we present the most recent data from clinical trials with some of the promising inhibitors of angiogenesis.Agents that target the vascular endothelial growth factor signaling pathway are the furthest along in clinical development.
Gerald A. Soff, Anaadriana Zakarija
openaire +3 more sources
Perillyl Alcohol Is an Angiogenesis Inhibitor [PDF]
The Journal of Pharmacology and Experimental Therapeutics, 2004 Aberrant angiogenesis is essential for the progression of solid tumors and hematological malignancies. Thus, antiangiogenic therapy is one of the most promising approaches to control cancer. In the present work, we examined the ability of perillyl alcohol (POH), a dietary monoterpene with well-established tumor chemopreventive and chemotherapeutic ...
Loutrari, H. +6 more
openaire +2 more sources
Maspin is an angiogenesis inhibitor
Nature Medicine, 2000Maspin, a unique member of the serpin family, is a secreted protein encoded by a class II tumor suppressor gene whose downregulation is associated with the development of breast and prostate cancers. Overexpression of maspin in breast tumor cells limits their growth and metastases in vivo.
Olga V. Volpert +3 more
openaire +3 more sources
Inhibitors of Tumor Angiogenesis
2008Inhibitors of Tumor ...
Harris, Adrian L, GENERALI, DANIELE
openaire +3 more sources